- Home
- GCV vs AGEN Comparison
GCV vs AGEN Comparison
Compare GCV & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCV
- AGEN
- Stock Information
- Founded
- GCV 1988
- AGEN 1994
- Country
- GCV United States
- AGEN United States
- Employees
- GCV N/A
- AGEN N/A
- Industry
- GCV Finance/Investors Services
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GCV Finance
- AGEN Health Care
- Exchange
- GCV Nasdaq
- AGEN Nasdaq
- Market Cap
- GCV 76.3M
- AGEN 87.7M
- IPO Year
- GCV N/A
- AGEN 2000
- Fundamental
- Price
- GCV $3.85
- AGEN $6.07
- Analyst Decision
- GCV
- AGEN Buy
- Analyst Count
- GCV 0
- AGEN 4
- Target Price
- GCV N/A
- AGEN $13.00
- AVG Volume (30 Days)
- GCV 57.9K
- AGEN 1.2M
- Earning Date
- GCV 01-01-0001
- AGEN 08-07-2025
- Dividend Yield
- GCV 13.04%
- AGEN N/A
- EPS Growth
- GCV N/A
- AGEN N/A
- EPS
- GCV N/A
- AGEN N/A
- Revenue
- GCV N/A
- AGEN $99,524,000.00
- Revenue This Year
- GCV N/A
- AGEN $12.69
- Revenue Next Year
- GCV N/A
- AGEN N/A
- P/E Ratio
- GCV N/A
- AGEN N/A
- Revenue Growth
- GCV N/A
- AGEN N/A
- 52 Week Low
- GCV $3.15
- AGEN $1.38
- 52 Week High
- GCV $4.58
- AGEN $18.74
- Technical
- Relative Strength Index (RSI)
- GCV 61.20
- AGEN 67.49
- Support Level
- GCV $3.78
- AGEN $4.34
- Resistance Level
- GCV $3.84
- AGEN $5.22
- Average True Range (ATR)
- GCV 0.06
- AGEN 0.46
- MACD
- GCV 0.00
- AGEN 0.02
- Stochastic Oscillator
- GCV 100.00
- AGEN 93.01
About GCV Gabelli Convertible and Income Securities Fund Inc. (The)
GABELLI CONVERTIBLE & INCOME SECURITIES FUND INC is a diversified closed-end management investment company. Its investment objective is to seek a high level of total return through a combination of current income and capital appreciation by investing in convertible securities. The company invests in various portfolios such as Health Care, Financial Services, Real Estate Investment Trust, Energy and Utilities, Telecommunications, Food and Beverage, Aerospace and Automotive and others. All the operation of the group is operated through the regions of United States.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).